[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"opioid-craving\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:opioid-craving":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100478587","phase-2-evaluating-buspirone-to-treat-opioid-withdrawal-100478587",false,"NCT05511909","Evaluating Buspirone to Treat Opioid Withdrawal","Evaluating a Mechanistically-Supported Pharmacotherapy to Treat Opioid Withdrawal","Inclusion Criteria:\n\n* Aged 18-75\n* Opioid positive urine sample\n* Current moderate-severe opioid use disorder with evidence of physical dependence\n* Interested in undergoing opioid detoxification\n\nExclusion Criteria:\n\n* Being pregnant or breastfeeding\n* Enrolled in methadone or buprenorphine maintenance treatment\n* Allergic to study medication or taking medications that are contraindicated with study medication (e.g., CYP3A4 inhibitors or inducers and\u002For monoamine oxidase (MAO) inhibitors)\n* Significant mental health or physical disorder, or life circumstance, that is expected to interfere with study participation (detailed further in protection of human subjects form).\n* Hypotension and\u002For prolonged QTc interval","ALL","18 Years","75 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The investigators propose a rigorous, Phase II, three-group, placebo-controlled double-blind randomized controlled trial (RCT) to evaluate the efficacy of buspirone for both withdrawal and craving among individuals with opioid use disorder (OUD) undergoing a standardized stepwise taper. During this 10 to 12-day residential study, participants with OUD will be enrolled, stabilized on a short-acting opioid, undergo an opioid stepwise taper, and complete a post-taper observation period where participants will have the opportunity to initiate long-term buprenorphine or extended-release naltrexone.",[27,28,29,30],"Opioid Use Disorder","Opioid Withdrawal","Opioid Craving","Anxiety","RECRUITING","2026-04-27",{"date":34,"type":35},"2026-05-01","ACTUAL",{"date":37,"type":35},"2023-03-15",{"date":39,"type":21},"2027-03-31",{"name":41,"class":42},"University of Maryland, Baltimore","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":43},"100447668","developing-a-clinical-outcome-assessment-for-opioid-craving-100447668","NCT05109429","Developing a Clinical Outcome Assessment for Opioid Craving","Inclusion Criteria:\n\n* 18 years of age and older\n* Opioid-positive urine sample at admission visit (excluding individuals receiving Naltrexone).\n* Current opioid use disorder per Diagnostic Statistical Manual (DSM)-5\n* Currently in treatment for opioid use disorder\n\nExclusion Criteria:\n\n* Being pregnant or breastfeeding, or may become pregnant during the trial\n* History of psychosis or mania or other serious psychiatric disorders assessed by the Mini International Neuropsychiatric Interview\n* Past 30-day suicidal behavior assessed by the Columbia Suicide Severity Rating Scale\n* Have circumstances that would interfere with study participation (e.g., impending jail).\n* Positive for illicit substances except opioids and cannabis\n* Current substance use disorder other than opioid or nicotine\n* Current intoxication",true,{"count":52,"type":21},81,[54],"NA","The purpose of this study is to collect information about opioid craving so that the investigators can develop an opioid craving assessment to improve treatments for individuals with opioid use disorder. To collect this information, the investigators are recruiting individuals in treatment for opioid use disorder who will complete cue-induced opioid craving tasks where these individuals will: (1) look at pictures of neutral objects and touch neutral objects (e.g., water bottles or flashlights), (2) look at opioid-related images, and (3) look and touch opioid-related objects. Participants will then complete a one-on-one interview about the thoughts, feelings and physical sensations the participants experienced during the cue-induced craving session. Participants will also complete questionnaires and existing opioid craving assessments. Finally, participants will provide formal feedback about existing opioid craving assessments with cognitive interviews.",[29,27,57],"Measure Development","2025-10-21",{"date":60,"type":35},"2025-10-23",{"date":62,"type":35},"2022-03-03",{"date":64,"type":21},"2026-09-30",{"name":66,"class":42},"Johns Hopkins University",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":43},"100441404","phase-2-assessing-a-clinically-meaningful-opioid-withdrawal-phenotype-100441404","NCT05027919","Assessing a Clinically-meaningful Opioid Withdrawal Phenotype","Inclusion Criteria:\n\n* 18 years - 65 year old\n* Opioid-positive urine sample\n* Current opioid use disorder with evidence of physical dependence\n* Interest in undergoing opioid taper\n\nExclusion Criteria:\n\n* Evidence of physical dependence on alcohol or benzodiazepines that requires medical intervention\n* Being pregnant or breastfeeding\n* Enrolled in methadone or buprenorphine maintenance treatment\n* Clinically significant hypotension (\\\u003C90\u002F60mmHg) or bradycardia (\\\u003C45bpm)\n* History of myocardial infarction\n* Subjects who are positive for hepatitis B surface antigen and\u002For hepatitis C antibody with liver function tests outside the normal range (persons with a positive hepatitis C antibody and normal liver functions tests are NOT excluded from the study)\n* Significant mental health or physical disorder, or life circumstances, that is expected to interfere with study participation","65 Years",{"count":75,"type":21},60,[24],"Evaluate individual differences in the expression of opioid withdrawal symptoms in persons with opioid use disorder (OUD) while completing a clinically-indicated medication taper.",[28,27,29],"2025-09-05",{"date":81,"type":35},"2025-09-12",{"date":83,"type":35},"2021-12-01",{"date":85,"type":21},"2027-02-28",{"name":41,"class":42}]